References
- 1. Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995; 374: 1-5.10.1016/0014-5793(95)01050-O
- 2. Nizet V, Gallo RL. Cathelicidins and innate defense against invasive bacterial infection. Scand J Infect Dis 2003; 35: 670-676.10.1080/0036554031001562914620153
- 3. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol. 2002; 169:3883-3891.10.4049/jimmunol.169.7.388312244186
- 4. Nijnik A, Pistolic J, Wyatt A, Tam S, Hancock R. Human Cathelicidin Peptide LL-37 Modulates the Effects of IFN-γ on APCs. The Journal of Immunology 2009; 183 (9) 5788-5798.10.4049/jimmunol.090149119812202
- 5. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, The human antimicrobial and chemotactic peptides LL-37 are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96 (9): 3086-3093.10.1182/blood.V96.9.3086
- 6. Davidson DJ. The cationic antimicrobial peptide LL37 modulates dendritic cell differentiation. J Immunol 2004; 172(2):1146-1156.10.4049/jimmunol.172.2.114614707090
- 7. Bucki R, Leszczynska K, Namiot A, Sokolowski W.Cathelicidin LL37: a multitask antimicrobial peptide. Arch Immunol Ther Exp 2010; 58:15-25.10.1007/s00005-009-0057-220049649
- 8. Kandler K, Shaykhiev R, Kleemann P,Klesca F, Lohoff M, Vogelmeier . C The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands, Int. Immunol. (2006) 18 (12): 1729-173610.1093/intimm/dxl10717041145
- 9. Mookherjee N, Brown KL, Bowdish D, Doria S, Falsafi R, Hokamp K et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. The Journal of Immunology 2006; 176: 2455-2464.10.4049/jimmunol.176.4.245516456005
- 10. Doss M, White M, Tecle T, Hartshorn KL, Human defensins and LL-37 in mucosal immunity, Journal of Leukocyte Biology 2010; 87 (1);79-9210.1189/jlb.0609382716708619808939
- 11. Golec M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. Ann Agric Environ Med 2007; 14(1):1-4.
- 12. Rivas-Santiago B, Hernandez-Pando R, Carranza C. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infection and Immunity 2008; 76 (3): 935-94110.1128/IAI.01218-07225880118160480
- 13. Cole AM, Lehrer RI. Minidefensins and other antimicrobial peptides: candidate anti-HIV microbicides. Expert Opin Ther Targets 2003; 7:329-341. doi: 10.1517/eott.7.3.329.2243610.1517/eott.7.3.329.22436
- 14. Andersson E, Rydengård V, Sonesson A, Mörgelin M, Björck L, Schmidtchen A. Antimicrobial activities of heparin-binding peptides, 2004, European Journal of Biochemistry 271 (6);1219-122610.1111/j.1432-1033.2004.04035.x15009200
- 15. Taylor JM, Han Z. Purinergic Receptor Functionality Is Necessary for Infection of Human Hepatocytes by Hepatitis Delta Virus and Hepatitis B Virus, PLoS One. 2010; 5(12): e15784.doi: 10.1371/journal.pone.001578410.1371/journal.pone.0015784300496121187936
- 16. Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B et al. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. Journal of Virology 2006; 80 (21): 10579-10590.10.1128/JVI.00941-06164178316928753
- 17. Kaneider NK, Djanani A, Wiedermann CJ. Heparan sulfate proteoglycan-involving immunomodulation by cathelicidin antimicrobial peptides and PR39”. The Scientific World Journal 2007; 7:1832-1838.10.1100/tsw.2007.285590085018040544
- 18. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96(22):12766-12771.10.1073/pnas.96.22.127662309010535997
- 19. Sørensen O, Bratt T, Anders H, Madsen MT, Borregaard N. The human antibacterial cathelicidin, hCAP-18, is bound to lipoproteins in plasma, The Journal of Biological Chemistry 1999; 274(32): 22445-22451
- 20. Guidelines For Viral Hepatitis Surveillance And Case Management, 2009 http://www.cdc.gov/hepatitis/SurveillanceGuidelines.htm).
- 21. Laborator Synevo.Ghidul serviciilor medicale. Referinte specifice tehnologiei de lucru utilizate editia. Catalog 2007-2008: 555-562 http://www.synevo.com.ro
- 22. Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. Journal of Virology 2003; 77 (8): 4781-4793.10.1128/JVI.77.8.4781-4793.200315213112663785
- 23. Eckels DD, Wang H, Bian TH, Tabatabai N, Gill JC. Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev 2000; 174: 90-97.10.1034/j.1600-0528.2002.017403.x10807509
- 24. Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M et al. Immune effectors required for hepatitis B virus clearance. PNAS 2010; 107 (2): 798-802.10.1073/pnas.0913498107281893320080755
- 25. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-765.10.1002/hep.510240402
- 26. Frese M, Schwarzle V, Barth K et al. Interferon- gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35: 694-70310.1053/jhep.2002.31770
- 27. Kondo Y, Sung VM, Machida K, Liu M, Lai MM. Hepatitis C virus infects T cells and affects interferon- gamma signaling in T cell lines. Virology 2007; 361(1): 161-173.10.1016/j.virol.2006.11.009
- 28. Tjabringa GS, Rabe K, Hiemstra P. The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung Pulmonary Pharmacology & Therapeutics 2009; 18 (5); 321-327.10.1016/j.pupt.2005.01.001
- 29. Sørensen, O, Cowland JB, Askaa J, Borregaard N. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J. Immunol Methods 1997; 206: 53-59.10.1016/S0022-1759(97)00084-7
- 30. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 2009; 48(4):418-424.10.1086/596314694431119133797
- 31. Yamschchikov AV, Kurbatova EV, Kumari M, Blumberg HM, Ziegler TR, Ray SM et al. Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis. Am J Clin Nutr September 2010; 92 (3) 603-611.10.3945/ajcn.2010.29411292153720610636
- 32. Iacob SA, Panaitescu E, Iacob DG, Cojocaru M. The human cathelicidin LL37 peptide has high plasma levels in B and C hepatitis related to viral activity but not to 25-hydroxyvitamin D plasma level. Rom J Intern Med 2012;50(3):217-23.